What is claimed is:
1. An isolated polynucleotide comprising the hYAK3-2 polypeptide encoding sequence contained in SEQ ID NO:1 or 3.
2. The polynucleotide of SEQ ID NO: 1 or 3.
3. A polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide of claim 2.
4. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a hYAK3-2 polypeptide comprising an amino acid sequence of SEQ ID NO:2 or 4 when said expression system is present in a compatible host cell.
5. A host cell comprising the expression system of claim 4.
6. A process for producing a hYAK3-2 polypeptide comprising culturing a host of claim 5 and under conditions sufficient for the production of said polypeptide.
7. The process of claim 6 which further includes recovering the polypeptide from the culture.
8. A process for producing a cell which produces a hYAK3-2 polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 4 such that the host cell, under appropriate culture conditions, produces a hYAK3-2 polypeptide.
9. Cells produced by the process of claim 8.
10. A hYAK3-2 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 or 4 over its entire length.
11. The polypeptide of claim 10 which comprises the amino acid sequence of SEQ ID NO:2 or 4.
12. The polypeptide of SEQ ID NO: 2 or 4.
13. A hYAK3-2 polypeptide prepared by the method of claim 6.
14. An antibody immunospecific for the hYAK3-2 polypeptide of claim 10
15. A method for the treatment of a subject in need of enhanced hYAK3-2 polypeptide activity comprising:
(a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; andor
(b) providing to the subject hYAK3-2 polynucleotide in a form so as to effect production of said polypeptide activity in vivo.
16. A method for the treatment of a subject having need to inhibit hYAK3-2 polypeptide activity comprising:
(a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; andor
(b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; andor
(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor.
17. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of hYAK3-2 polypeptide in a subject comprising:
(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said hYAK3-2 polypeptide in the genome of said subject; andor
(b) analyzing for the presence or amount of the hYAK3-2 polypeptide expression in a sample derived from said subject.
18. A method for identifying compounds which inhibit (antagonize) or agonize the hYAK3-2 polypeptide which comprises:
(a) contacting a candidate compound with cells which express the hYAK3-2 polypeptide (or cell membrane expressing hYAK3-2 polypeptide) or respond to hYAK3-2 polypeptide; and
(b) observing the binding, or stimulation or inhibition of a functional response; or comparing the ability of the cells (or cell membrane) which were contacted with the candidate compounds with the same cells which were not contacted for hYAK3-2 polypeptide activity.
19. An agonist identified by the method of claim 18.
20. An antagonist identified by the method of claim 18.
21. A polypetide obtainable by expressing a nucleotide sequence comprising that of SEQ ID NO:1 or 3.
22. A method of treating hematopoietic cellular deficiency comprising administering an hYAK3-2 antagonist to a patient in need thereof.
23. The hematopoietic cellular deficiency of claim 22 which is anemia.
24. The hematopoietic cellular deficiency of claim 22 which is neutropenia.
25. The hematopoietic cellular deficiency of claim 22 which is cytopenia.
26. The hematopoietic cellular deficiency of claim 22 which is drug-induced anemias.
27. The hematopoietic cellular deficiency of claim 22 which is polycythemia.
28. The hematopoietic cellular deficiency of claim 22 which is myelosuppression.
29. The hematopoietic cellular deficiency of claim 22 which is anemia due to renal insufficiency.
30. The hematopoietic cellular deficiency of claim 22 which is anemia due to chronic disease, such as autoimmunity or cancer.
31. The antagonist of claim 22 consisting from the group of
(a) a compound of SEQ ID NO: 6;
(b) a compound of SEQ ID NO:7; and
(c) a compound of SEQ ID NO: 8.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An industrial vehicle comprising:
an armrest extending in a front-and-rear direction of the vehicle;
a plurality of operating members for controlling a loading operation of the vehicle arranged on the front portion of the armrest, the operating members comprising a first operating member for controlling an actuator for loading, a second operating member for controlling the actuator and a third operating member;
a mast connected to the actuator; and
a fork connected to the mast, wherein the first operating member is operated for tilting the mast frontward and backward, the second operating member being operated for automatically stopping the tilt of the mast at a position where the fork becomes horizontal,
wherein the armrest has a first region and a second region adjacent to the first region, the first region having a first top surface on which the first and third operating members are arranged, the second region being formed by a pad, the second region having a second top surface and a front surface, the second top surface being higher than the first top surface, the second operating member is arranged on the front surface of the second region.
2. The industrial vehicle according to claim 1, wherein the second operating member is arranged behind the first operating member.
3. The industrial vehicle according to claim 1, further comprising a guard arranged on the front surface of the second region, the second operating member being surrounded by the guard.
4. The industrial vehicle according to claim 3, wherein the second operating member is a push-on-push-off switch.
5. The industrial vehicle according to claim 4, wherein the guard is a cylinder, a first opening for confirming a position of the switch being formed in the cylinder in a circumferential direction of the cylinder.
6. The industrial vehicle according to claim 5, wherein the first opening is a notch.
7. The industrial vehicle according to claim 4, wherein the guard is a cylinder, a second opening for draining water being formed in the cylinder in a circumferential direction of the cylinder.
8. The industrial vehicle according to claim 7, wherein the second opening is a notch.
9. The industrial vehicle according to claim 4, wherein the second operating member is a switch in which light is emitted when the switch is on and in which the light is quenched when the switch is off.
10. The industrial vehicle according to claim 1, wherein the second region includes a recess in its front surface, the second operating member being placed in the recess, so that the second operating member is guarded in the recess.
11. The industrial vehicle according to claim 1, wherein the front surface of the second region is inclined with respect to the top surface of the first region in a rearward direction of the armrest.
12. The industrial vehicle according to claim 1, wherein the first region is located on the front side of the armrest while the second region being located behind the first region.
13. The industrial vehicle according to claim 1, wherein the first region is a lever arranged region and the second region is a rest region.
14. The industrial vehicle according to claim 1, wherein the second region further includes an arm pad portion for supporting an arm of an operator of the vehicle and a palm pad portion for supporting a palm of the operator.